1
One Sample
A simple at-home finger-prick collected over 5 days. No clinic visits, no fasting, friction-free scaling.
Investor Relations
Building the infrastructure for preventive medicine.
We turn a single finger-prick into a continuously learning virtual twin. A dual-engine model monetizing consumer wellness today to build the clinical multi-cancer detection AI of tomorrow.
- Clinical pilot, Cleveland Clinic Abu Dhabi
- Microsoft for Startups
- $5M raised
Our Core Asset
Your blood. 30,000 biomarkers.
Your blood. 30,000 biomarkers.
Virtual twin.
Standard blood tests read 20 to 30 parameters. BioTwin reads over 30,000 biomarker signals from a single finger-prick using mass spectrometry, creating an unparalleled dataset for predictive AI.
2
30,000 Signals
High-resolution mass spectrometry captures a complete metabolic signature, not just a targeted checklist.
3
3 Programs
Raw data is organized into actionable health programs: Healthspan and Longevity, Elite Human Optimization, and Weight Management.
4
Virtual Twin
A living mathematical model that learns retroactively. When our research team adds a new analysis, the twin updates without a new kit.
Go-to-market strategy
Consumer today.
Consumer today.
Clinical tomorrow.
The data required to train clinical AI for complex diseases is vast and expensive to acquire. BioTwin solves this cold-start problem through a self-funding data flywheel.
-
TwinMe (Consumer): We deliver immediate value through 3 commercial wellness programmes (Longevity, Elite Optimization, Weight) generating immediate revenue.
-
BioTwin (Clinical): Every anonymized finger-prick continuously expands our multi-omics database, directly training our predictive models for oncology and chronic diseases.
N=1
Personalized
Medicine
Medicine
"By mapping individual trajectories rather than population averages, we can detect minute biological deviations before they manifest as clinical symptoms."
Scientific Pipeline
Active clinical traction.
Our virtual twin technology is already deployed in real-world clinical environments.
Clinical pilot, active
Abu Dhabi, UAE Cleveland Clinic Abu Dhabi
BioTwin's first clinical pilot delivers results today through partner physicians at Cleveland Clinic Abu Dhabi. The programme is under the regulatory framework of the United Arab Emirates.
Current screening: Breast cancer · Colorectal cancer
Performance: Current models demonstrate 0.78 sensitivity across 6 cancer types using multi-omics integration.
Research in progress
Global Broader clinical pipeline
Beyond the UAE pilot, BioTwin runs active research programs globally, supported by over 50 published studies validating our biomarker signatures.
- Oncology: Lung, Pancreas, Prostate, Ovarian
- Neurology: Alzheimer's, Parkinson's, Depression
- Cardiology: Heart failure, Hypertension
These are scientific projects, and TwinMe kit data contributes directly to them.
Branchenvalidierung
Branchenvalidierung
Globale Marktführer investieren in die Virtual-Twin-Technologie als grundlegende Infrastruktur für die Präzisionsmedizin.
Dassault Systemes
"Es wird ein Vorher und Nachher des virtuellen Zwillings des menschlichen Körpers geben."
Das Living Heart Project und die Emma Twin Initiative treiben die Virtual-Twin-Technologie für die kardiale Versorgung und personalisierte Medizin voran.
Nvidia
Gesundheitliche virtuelle Zwillinge, gestützt durch KI-Simulation
Die Gesundheitsplattformen von NVIDIA unterstützen beschleunigte medizinische Simulationen und eine skalierbare Virtual-Twin-Infrastruktur.
Twin Health
Ganzkörper-Digitalzwilling für metabolische Gesundheit
Veröffentlichte peer-reviewte klinische Ergebnisse, die messbare metabolische Verbesserungen durch zwillingsbasierte Modellierung belegen.
Warum das wichtig ist: Investitionen globaler Marktführer bestätigen, dass die Virtual-Twin-Infrastruktur zu einer grundlegenden Ebene der Präzisions- und Präventivmedizin wird.
Join our mission
We are building the definitive biological dataset for preventive medicine. To access our data room, clinical results, or speak with leadership, reach out today.
Contact Investor Relations